- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01858896
GLP-1 and Hypoglycemia
March 5, 2024 updated by: Stephen N. Davis, MBBS, University of Maryland, Baltimore
Hypoglycemia Associated Autonomic Dysfunction
Low blood sugar can negatively affect how blood vessels function, and this can lead to an increase in the risk for heart attacks, strokes and other problems related to the stiffening and blockage of blood vessels.
The purpose of this study is to learn if and how glucagon-like peptide-1 (GLP-1; a naturally occurring hormone in the gut) changes the effects that low blood sugar levels have on blood vessels.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
28
Phase
- Early Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21201
- University of Maryland, Baltimore
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 45 years (Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- 14 (7 males, 7 females) healthy controls age 30-60 yr.
- 14 (7 males, 7 females) people with type 2 DM age 30-60 yr.
- For type 2 DM: HbA1c 6-10.0%
- No significant diabetic tissue complications (i.e. history of retinopathy, neuropathy, stasis ulcers, etc.)
- Body mass index >25kg • m-2
Exclusion Criteria:
-
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Glucagon-Like Peptide -1 (GLP-1) infusion
Infusion of GLP-1 during experimental period
|
GLP-1 infusion during experimental period
Other Names:
|
Placebo Comparator: Saline Infusion
Saline infusion during experimental period
|
Saline infusion (placebo) during experimental period
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Plasminogen Activation inhibitor-1 (PAi-1)
Time Frame: change from baseline to end of clamp period
|
measurements of change in PAi-1 at baseline and during the end of the glucose clamp period (2 hours)
|
change from baseline to end of clamp period
|
Change in Flow mediated dilation (FMD)
Time Frame: change from baseline and end of clamp
|
flow mediated dilation of the brachial artery will be measured for change from baseline and end of glucose clamp (~4 hours)
|
change from baseline and end of clamp
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Stephen N Davis, MBBS, University of Maryland, Baltimore
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2013
Primary Completion (Estimated)
February 1, 2025
Study Completion (Estimated)
February 1, 2026
Study Registration Dates
First Submitted
May 13, 2013
First Submitted That Met QC Criteria
May 16, 2013
First Posted (Estimated)
May 21, 2013
Study Record Updates
Last Update Posted (Actual)
March 6, 2024
Last Update Submitted That Met QC Criteria
March 5, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HP00055308
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 2 Diabetes Mellitus
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
US Department of Veterans AffairsAmerican Diabetes AssociationCompletedType 2 Diabetes MellitusUnited States
-
Dexa Medica GroupCompletedType-2 Diabetes MellitusIndonesia
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
AstraZenecaRecruiting
Clinical Trials on Glucagon-Like Peptide- 1 (GLP-1) infusion
-
University of ChicagoCompleted
-
University Hospital, Gentofte, CopenhagenCompletedObesity | Incretin ActionDenmark
-
Herlev HospitalUniversity of Copenhagen; The Danish Medical Research Council; The Danish Diabetes...Completed
-
Johns Hopkins UniversityTerminatedBariatric SurgeryUnited States
-
Uppsala UniversityKarolinska InstitutetCompletedFunctional Gastrointestinal DisordersSweden
-
University of Missouri-ColumbiaAmerican Society for Metabolic and Bariatric SurgeryRecruitingHypertension | Diabetes Mellitus | Metabolic Syndrome | Morbid Obesity | Obstructive Sleep Apnea of AdultUnited States
-
University Hospital, Gentofte, CopenhagenCompletedType 1 Diabetes | Type 2 DiabetesDenmark
-
Uppsala UniversityKarolinska Institutet; University of CopenhagenCompletedPhysiology | Gastroenterology | EndocrinologySweden
-
Johns Hopkins UniversitySociety of Critical Care MedicineTerminatedHypoglycemia | Critically IllUnited States
-
Mayo ClinicNational Center for Research Resources (NCRR); Rose Pharma A/SCompletedIrritable Bowel Syndrome Constipation PredominantUnited States